Shares of TG Therapeutics (TGTX) tumbled 5.37% during pre-market trading on Monday, following the release of the company's second-quarter 2026 financial results. The drop came as investors reacted to a significant earnings miss, overshadowing a robust revenue beat and an upward revision to the company's full-year outlook.

The biotech firm reported earnings per share of $0.05, widely missing the consensus analyst estimate of $0.33. Net income fell sharply to $7.8 million from $28.2 million in the prior-year period, driven by a substantial increase in research and development expenses and higher selling, general and administrative costs. R&D spending nearly tripled to $95.3 million, while SG&A expenses rose to $82.1 million, reflecting investments in the commercialization of its multiple sclerosis treatment, BRIUMVI.

On the positive side, total revenue for the quarter surged 70% year-over-year to $240.3 million, beating expectations. BRIUMVI U.S. net product revenue reached $227.7 million, up about 64% from a year ago. Management also raised its full-year 2026 total global revenue target to approximately $950 million, citing strong sales momentum for BRIUMVI, which is tracking toward a $1 billion annualized U.S. revenue run rate exiting the year. Despite these encouraging signs, the bottom-line miss and the dramatic decline in net income appeared to weigh heavily on pre-market sentiment, triggering the sell-off.